Table 4.

Meta-analysis of change from baseline in HAM-A single items at week 6/8 (FAS, MMRM, SES).

Item	Treatment a	All studies analysis (NCT00839423, NCT00635219, NCT00735709, NCT00672958, NCT00672620)					Three studies analysis (NCT00839423, NCT00635219, NCT00735709)
		N	∆ Placebo	SE	p-value	Heterogeneity p-value	N	∆ Placebo	SE	p-value	Heterogeneity p-value
7: Somatic Muscular b	Placebo	695	·	·	·		335	·
	VOR 5 mg	711	−0.15	0.06	0.021	0.239	344	−0.21	0.08	0.005	0.740
	VOR 10 mg	319	−0.15	0.08	0.055	0.837	319	−0.15	0.08	0.055	0.837
8: Somatic Sensory b	Placebo	695	·	·	·		335	·
	VOR 5 mg	711	−0.10	0.05	0.052	0.866	344	−0.15	0.08	0.050	0.765
	VOR 10 mg	319	−0.18	0.11	0.126	0.121	319	−0.18	0.11	0.126	0.121
9: Cardiovascular b	Placebo	695	·	·	·		335	·
	VOR 5 mg	711	−0.04	0.12	0.722	0.001	344	−0.18	0.11	0.097	0.140
	VOR 10 mg	319	−0.17	0.13	0.182	0.073	319	−0.17	0.13	0.182	0.073
10: Respiratory b	Placebo	694	·	·	·		335	·
	VOR 5 mg	711	−0.16	0.09	0.074	0.035	344	−0.24	0.11	0.030	0.133
	VOR 10 mg	319	−0.19	0.11	0.084	0.131	319	−0.19	0.11	0.084	0.131
11: Gastrointestinal b	Placebo	695	·	·	·		335	·
	VOR 5 mg	711	−0.10	0.05	0.060	0.540	344	−0.20	0.08	0.011	0.990
	VOR 10 mg	319	−0.22	0.12	0.069	0.089	319	−0.22	0.12	0.069	0.089
12: Genitourinary b	Placebo	695	·	·	·		335	·
	VOR 5 mg	711	−0.15	0.06	0.020	0.251	344	−0.24	·0.08	0.002	0.457
	VOR 10 mg	319	−0.28	0.08	<.001	0.553	319	−0.28	0.08	<0.001	0.553
13: Autonomic b	Placebo	695	·	·	·		335	·
	VOR 5 mg	711	−0.01	0.07	0.897	0.206	344	−0.12	0.08	0.123	0.536
	VOR 10 mg	319	−0.27	0.12	0.025	0.103	319	−0.27	0.12	0.025	0.103
HAM-A total score	Placebo	695					335
	VOR 5 mg	711	−0.25	0.10	0.012	0.012	344	−0.39	0.08	<0.001	0.370
	VOR 10 mg	319	−0.47	0.12	<.001	0.119	319	−0.47	0.12	<0.001	0.119

^aThe 10 mg vortioxetine (VOR) dose was tested only in the three positive studies; thus, the data in the 10 mg dose rows for the ‘All studies’ and the ‘Three studies’ analyses are identical.

^bDefinition of item provided in Table 2.